X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8) 8
aged (5) 5
female (5) 5
humans (5) 5
metastases (5) 5
middle aged (5) 5
mutation (5) 5
open-label (5) 5
abridged index medicus (4) 4
adult (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
male (4) 4
medicine, general & internal (4) 4
melanoma (4) 4
metastasis (4) 4
metastatic melanoma (4) 4
oncology (4) 4
survival (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
cancer (3) 3
chemotherapy (3) 3
melanoma - drug therapy (3) 3
melanoma - genetics (3) 3
multicenter (3) 3
patients (3) 3
proto-oncogene proteins b-raf - genetics (3) 3
acquired-resistance (2) 2
aged, 80 and over (2) 2
azetidines - administration & dosage (2) 2
braf (2) 2
clinical trials (2) 2
dabrafenib (2) 2
disease-free survival (2) 2
double-blind method (2) 2
drug therapy (2) 2
fever (2) 2
improved survival (2) 2
indoles - administration & dosage (2) 2
kaplan-meier estimate (2) 2
medical prognosis (2) 2
mek inhibitors (2) 2
melanoma - mortality (2) 2
paclitaxel (2) 2
piperidines - administration & dosage (2) 2
proto-oncogene proteins b-raf - antagonists & inhibitors (2) 2
risk factors (2) 2
sulfonamides - administration & dosage (2) 2
survival analysis (2) 2
survival rate (2) 2
trial (2) 2
tumors (2) 2
vemurafenib (2) 2
young adult (2) 2
adjuvant (1) 1
analysis (1) 1
anaplastic lymphoma kinase (1) 1
anti-pd-1 (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibody (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
apoptosis (1) 1
azetidines - adverse effects (1) 1
b7-h1 antigen - antagonists & inhibitors (1) 1
bevacizumab (1) 1
bevacizumab - administration & dosage (1) 1
biomarkers (1) 1
biomarkers, tumor - genetics (1) 1
braf inhibitor (1) 1
braf-mutant melanoma (1) 1
breast cancer (1) 1
breast neoplasms - drug therapy (1) 1
breast neoplasms - metabolism (1) 1
cancer therapies (1) 1
carboplatin (1) 1
carboplatin - administration & dosage (1) 1
carcinoma, non-small-cell lung - drug therapy (1) 1
carcinoma, non-small-cell lung - genetics (1) 1
carcinoma, non-small-cell lung - mortality (1) 1
carcinoma, non-small-cell lung - secondary (1) 1
care and treatment (1) 1
cells (1) 1
chemotherapy plus trastuzumab (1) 1
chemotherapy, adjuvant (1) 1
clinical study (1) 1
cobimetinib (1) 1
death (1) 1
dehydrogenases (1) 1
diarrhea (1) 1
docetaxel (1) 1
double-blind (1) 1
doxorubicin (1) 1
drug therapy, combination (1) 1
efficacy (1) 1
eortc qlq-c30 (1) 1
epidermal growth factor receptors (1) 1
exanthema (1) 1
extended follow-up (1) 1
fatigue (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 20, pp. 1867 - 1876
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 24, pp. 2288 - 2301
The addition of atezolizumab (anti–PD-L1 antibody) to a platinum-based chemotherapy regimen improved progression-free survival among patients who had not... 
PHASE-III TRIAL | CELLS | MULTICENTER | THERAPY | BEVACIZUMAB | ANTIBODY | OPEN-LABEL | CANCER | DOCETAXEL | CHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - secondary | Anaplastic Lymphoma Kinase | Neoplasm Metastasis - drug therapy | Immunotherapy | Female | Paclitaxel - administration & dosage | Bevacizumab - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Carboplatin - administration & dosage | Carcinoma, Non-Small-Cell Lung - mortality | Genes, erbB-1 | B7-H1 Antigen - antagonists & inhibitors | Receptor Protein-Tyrosine Kinases - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Lung cancer, Non-small cell | Drug therapy | Research | Epidermal growth factor receptors | Liver | Non-small cell lung carcinoma | Oncology | Lymphocytes T | Metastasis | Cancer therapies | Patients | Bevacizumab | Metastases | Immunosuppression | Chemotherapy | Motivation | Medical prognosis | PD-L1 protein | Paclitaxel | Carboplatin | Population | Death | Vascular endothelial growth factor | Genotypes | Apoptosis | Tumors
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 20, pp. 1877 - 1888
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 09/2019, Volume 37, Issue 25, pp. 2206 - 2206
PURPOSE The KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) with docetaxel, carboplatin, trastuzumab plus P (TCH+P) for the... 
TRIAL | LAPATINIB | SURVIVAL | MULTICENTER | EFFICACY | ONCOLOGY | NEOSPHERE | OPEN-LABEL | CHEMOTHERAPY PLUS TRASTUZUMAB | TH3RESA | PHYSICIANS CHOICE | RAPID COMMUNICATION
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.